Poland· PL-100474751
Nexviadyme
A avalglucosidase alfa product containing avalglucosidasum alfa, registered in Poland by Sanofi B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Avalglucosidase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB22 (avalglucosidase alfa), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Avalglucosidase alfa · ATC A16AB22
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of avalglucosidase alfa costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Avalglucosidase alfa · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- CH Switzerland$1265.54
The record
At a glance
URPL (Poland)- Active substance
- Avalglucosidasum alfa
- Manufacturer
- Sanofi B.V.
- Country
- Poland (PL)
- ATC code
- A16AB22
- ATC class
- Avalglucosidase alfa
- Defined daily dose
- 0.1 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991472498
- gtin05909991472467
- gtin05909991472481
- gtin05909991472474
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Avalglucosidase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNEXVIADYMESanofi B.V., Amsterdam
- SwitzerlandNexviadyme 100 mg, poudre pour solution à diluer pour perfusionSanofi-Aventis (Suisse) SA
- FinlandNexviadymeSanofi B.V.
- United KingdomNexviadyme 100mg powder for concentrate for solution for infusion vialsSanofi
- IrelandNexviadyme 100 mg powder for concentrate for solution for infusionSanofi B.V.
- IcelandNexviadymeGenzyme Europe B.V.
- NorwayNexviadymeSanofi B.V.
- BelgiumNexviadyme 100 mgSanofi
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nexviadyme
- Liechtenstein · Nexviadyme
- Norway · Nexviadyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/99ae874e-d545-4593-88ad-c16304e9249a GET /v1/drugs/99ae874e-d545-4593-88ad-c16304e9249a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do przygotowania koncentratu do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "100 mg",
"packaging": "05909991472498 ¦ Rpz ¦ EU/1/21/1579/003 ¦ 142947\n10 fiol. 100 mg proszku\n05909991472467 ¦ Rpz ¦ EU/1/21/1579/002 ¦ 142948\n5 fiol. 100 mg proszku\n05909991472481 ¦ Rpz ¦ EU/1/21/1579/004 ¦ 142949\n25 fiol. 100 mg proszku\n05909991472474 ¦ Rpz ¦ EU/1/21/1579/001 ¦ 142950\n1 fiol. 100 mg proszku",
"substance": "Avalglucosidasum alfa 100 mg",
"common_name": "Avalglucosidasum alfa",
"pl_product_id": "100474751",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about avalglucosidase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.